Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.

ABSTRACT:

Background

Only a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported.

Materials and methods

By means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy. We excluded patients with only BRAF, NRAS, or CKIT alterations and patients who received molecularly matched therapy for less than 15 days.

Results

We included 26 patients with a median follow-u

SUBMITTER: Connell E 

PROVIDER: S-EPMC11379651 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature